← Full evidence page

For the cleanest result, disable browser headers and footers.

Dediabetes Evidence Brief

SGLT2 Inhibitors for Diabetes: Evidence and Outcomes

Evidence related to SGLT2 inhibitor therapies in diabetes studies.

Brief accessed
—

Full evidence pagehttps://www.dediabetes.com/evidence/sglt2-inhibitors

Executive Summary

SGLT2 Inhibitors evidence appears to center on HbA1c.

Among 41 indexed studies and 4 interventions, the strongest signals are summarized from the available evidence. HbA1c appears to be one of the clearer current evidence signals.

  • Evidence is consistently positive across multiple studies.
  • Some evidence is positive, but results are not consistent across all studies.
  • Early findings are encouraging, but stronger trials are needed.

Caution

This summary reflects the currently indexed evidence and should not be interpreted as treatment advice.

Evidence Snapshot

Studies analyzed
41
Evidence relationships
100
Interventions
4
Outcomes
79
Strong evidence signals
4
Mixed evidence areas
1

Key Findings

  1. 01

    Across 10 studies, Empagliflozin shows a consistent strong positive signal for HbA1c.

  2. 02

    Across 5 studies, Empagliflozin shows a consistent moderate positive signal for Fasting Plasma Glucose (FPG).

  3. 03

    Across 6 studies, Empagliflozin shows a consistent evidence signal for Body weight.

  4. 04

    Across 9 studies, Dapagliflozin shows a consistent moderate positive signal for HbA1c.

Question Highlights

What outcomes has SGLT2 Inhibitors been studied for?

HbA1c, Fasting Plasma Glucose (FPG), and Body weight are among the most studied areas in relation to SGLT2 Inhibitors.

HbA1c, Fasting Plasma Glucose (FPG), and Body weight are among the best-supported options in the available evidence across 41 studies.

Read the full answer

Do SGLT2 Inhibitors lower HbA1c?

SGLT2 Inhibitors may lower HbA1c.

Strong evidence is based on 25 supporting studies.

Read the full answer

How does SGLT2 Inhibitors compare across studied outcomes?

HbA1c, Fasting Plasma Glucose (FPG), and Body weight have available evidence for SGLT2 Inhibitors, but the comparison requires review of the underlying studies.

Evidence is available for both Body weight and Fasting Plasma Glucose (FPG); the underlying studies are needed for a direct comparison.

Read the full answer

Evidence Categories

The evidence is organized by how consistently it supports a conclusion and how much research is available.

Well-Supported Interventions

The strongest and most consistent evidence for improving this outcome.

Evidence is consistently positive across multiple studies.

Why it matters

Consistent positive findings are easier to interpret than isolated or mixed results.

Interpretation

HbA1c appears to have a consistent beneficial signal in the indexed evidence.

Leading examples

HbA1c · Urinary albumin-to-creatinine ratio · Fasting Plasma Glucose (FPG)

Evidence basis: 16 evidence pairs - 31 studies

Findings Requiring Careful Interpretation

Results that vary across studies or depend on population, study design, duration, or comparator.

Some evidence is positive, but results are not consistent across all studies.

Why it matters

Mixed results suggest effects may depend on population, comparator, duration, or study design.

Interpretation

HbA1c is mixed in the currently indexed evidence.

Caution

Some supporting studies reported neutral, negative, or mixed findings.

Leading examples

HbA1c · Body weight · Fasting Plasma Glucose (FPG)

Evidence basis: 15 evidence pairs - 29 studies

Emerging Areas of Research

Early positive signals that require additional high-quality research.

Early findings are encouraging, but stronger trials are needed.

Why it matters

Promising signals can guide further review, but they should not be treated as settled evidence.

Interpretation

Triglycerides may have a beneficial signal, but the evidence base is still developing.

Caution

Current support is limited by study volume, RCT depth, or evidence strength.

Leading examples

Triglycerides · Alanine Aminotransferase (ALT) · All-cause mortality

Evidence basis: 7 evidence pairs - 11 studies

About this Evidence Brief

This brief summarizes research currently indexed by Dediabetes Evidence Intelligence. It is not a clinical guideline or personalized medical recommendation. Evidence classifications may change as additional studies are indexed.

Suggested citation

—